Analytical Performance of Different Laboratory Methods for Measuring Susoctocog-Alfa.

acquired haemophilia A assay methods recombinant porcine FVIII

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
18 Aug 2022
Historique:
received: 17 06 2022
revised: 14 08 2022
accepted: 16 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Recombinant porcine factor VIII (rpFVIII) is indicated for treating bleeding episodes in acquired haemophilia A, but there are few data regarding laboratory methods to adequately monitor treatment. This study involving three Italian laboratories aimed to evaluate the analytical performance of different assays for measuring rpFVIII. Five spiked rpFVIII samples (0.5-1.5 IU/mL) were analysed on three days, in triplicate, with eleven combinations of reagents (Werfen, Boston, MA, USA: SynthasIL and SynthaFax for one-stage assay, Chromogenix Coamatic FVIII for chromogenic assay), FVIII depleted plasmas (with or without von Willebrand factor-VWF) and calibrators (HemosIL human calibrator plasma, porcine calibrator diluted in FVIII deficient plasma with or without VWF). The assays were performed on ACL TOP analysers (Werfen, Boston, MA, USA). Intra- and inter-assay and inter-laboratory Coefficient of Variation (CV%) were calculated together with percentage of recovery (% recovery) on the expected value. The results showed that the reagent combinations reaching satisfactory analytical performance are: SynthasIL/human calibrator/deficient plasma+VWF (total recovery 99.4%, inter-laboratory CV 4.04%), SynthasIL/porcine calibrator/deficient plasma+VWF (total recovery 111%, inter-laboratory CV 2.75%) and Chromogenic/ porcine calibrator/deficient plasma+VWF (total recovery 96.6%, inter-laboratory CV 8.32%). This study highlights that the use of porcine standard (when available) and FVIII deficient plasma with VWF should be recommended.

Identifiants

pubmed: 36010349
pii: diagnostics12081999
doi: 10.3390/diagnostics12081999
pmc: PMC9407080
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Thromb Haemost. 2021 Mar;19(3):637-644
pubmed: 33306259
J Thromb Haemost. 2012 Apr;10(4):622-31
pubmed: 22321904
Br J Haematol. 2019 Mar;184(5):853-855
pubmed: 29528100
J Thromb Thrombolysis. 2019 Jan;47(1):129-133
pubmed: 30267246
Haemophilia. 2017 Jan;23(1):25-32
pubmed: 27511890
Eur J Haematol. 2015 Dec;95 Suppl 81:36-44
pubmed: 26679396
Blood Transfus. 2020 Jul;18(4):312-321
pubmed: 32698943
J Thromb Haemost. 2012 Aug;10(8):1478-85
pubmed: 22632160
Haemophilia. 2016 Nov;22(6):957-965
pubmed: 27353010
Blood. 2012 Jul 5;120(1):39-46
pubmed: 22618709
Haemophilia. 2017 Jan;23(1):33-41
pubmed: 27761964
Haemophilia. 2022 Mar;28(2):e39-e41
pubmed: 34878208
Blood Coagul Fibrinolysis. 2018 Jul;29(5):417-422
pubmed: 29608457
Haemophilia. 2020 Aug;26 Suppl 6:1-158
pubmed: 32744769
Haemophilia. 2022 May;28(3):515-519
pubmed: 35279922
Am J Hematol. 2002 Mar;69(3):192-9
pubmed: 11891806
Haematologica. 2000 Oct;85(10 Suppl):21-4; discussion 24-5
pubmed: 11187865
Haemophilia. 2018 Mar;24(2):e70-e74
pubmed: 29418045
Haemophilia. 2012 May;18(3):305-9
pubmed: 22531020
Blood Transfus. 2022 May;20(3):245-262
pubmed: 35175184
Blood. 2021 Jan 21;137(3):410-419
pubmed: 32766881
Res Pract Thromb Haemost. 2022 Mar 27;6(2):e12688
pubmed: 35356668
Am J Med. 1991 Nov 4;91(5A):23S-26S
pubmed: 1746592
Curr Opin Mol Ther. 2010 Oct;12(5):617-25
pubmed: 20886394
Eur J Hosp Pharm. 2021 May 19;:
pubmed: 34011555
J Virol. 2001 May;75(10):4551-7
pubmed: 11312325
Am J Hematol. 2017 Jul;92(7):695-705
pubmed: 28470674
Am J Med. 1991 Nov 4;91(5A):20S-22S
pubmed: 1746591
Blood. 1993 Mar 15;81(6):1513-20
pubmed: 8453098
Haemophilia. 2016 Mar;22(2):308-317
pubmed: 26278557
Thromb Res. 2020 Nov;195:125-127
pubmed: 32683151
Haemophilia. 2015 Mar;21(2):162-170
pubmed: 25623166
Haematologica. 2020 Jul;105(7):1791-1801
pubmed: 32381574
Haemophilia. 2003 Jan;9(1):104-9
pubmed: 12558786
Haemophilia. 2012 Sep;18(5):798-804
pubmed: 22512291

Auteurs

Cristina Novembrino (C)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122 Milan, Italy.

Ilaria Quaglia (I)

Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital Rozzano, 20089 Milan, Italy.

Angelo Claudio Molinari (AC)

Regional Reference Center for Inherited Bleeding Disorders, Istituto Giannina Gaslini, 16147 Genova, Italy.

Alessandra Borchiellini (A)

Regional Reference Center of Thrombotic and Hemorrhagic Disorders of the Adults, Department of Oncology and Hematology "Città della Salute e della Scienza", 10100 Turin, Italy.

Antonio Coppola (A)

Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, 43125 Parma, Italy.

Rita Carlotta Santoro (RC)

Hemostasis and Thrombosis Unit, Regional Reference Centre for Hemophilia, and Inherited Bleeding Disorders, AOPC, 88100 Catanzaro, Italy.

Massimo Boscolo-Anzoletti (M)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122 Milan, Italy.

Eleonora Galbiati (E)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122 Milan, Italy.

Ezio Zanon (E)

Haemophilia Centre-General Medicine, Padua University Hospital, 35128 Padua, Italy.

Alessandra Valpreda (A)

Regional Reference Center of Thrombotic and Hemorrhagic Disorders of the Adults, Laboratory Department "Città della Salute e della Scienza", 10100 Turin, Italy.

Classifications MeSH